Analyst Stock Ratings Upgrades

Analyst upgrades are typically bullish for a stock. When there is a stock upgrade, the analysts who rate the stock feel better about the company's future and typically either recommend someone holds or buys the stock. Updated 05/10/2025

Buy NowGet Alert
05/09/2025OUSTBuy Now
Ouster
$10.5529.67%WestPark Capital
Casey Ryan45%
 → $13.68UpgradeHold → BuyGet Alert
05/09/2025PTCTBuy Now
PTC Therapeutics
$44.4053.15%B of A Securities
Tazeen Ahmad54%
$55 → $68UpgradeNeutral → BuyGet Alert
05/09/2025EYEBuy Now
National Vision Holdings
$17.1722.32%Citigroup
Paul Lejuez64%
$13 → $21UpgradeNeutral → BuyGet Alert
05/09/2025WGSBuy Now
GeneDx Holdings
$59.1235.32%Jefferies
Tycho Peterson82%
 → $80UpgradeHold → BuyGet Alert
05/08/2025AFNBuy Now
Ag Growth International
——RBC Capital
Andrew Wong43%
$40 → $50UpgradeSector Perform → OutperformGet Alert
05/08/2025CERTBuy Now
Certara
$12.0016.67%Barclays
Luke Sergott51%
$11 → $14UpgradeEqual-Weight → OverweightGet Alert
05/08/2025MOSBuy Now
Mosaic
$32.7522.14%RBC Capital
Andrew Wong43%
$30 → $40UpgradeSector Perform → OutperformGet Alert
05/08/2025OPFIBuy Now
OppFi
$11.7514.89%JMP Securities
David Scharf67%
 → $13.5UpgradeMarket Perform → Market OutperformGet Alert
05/08/2025QDELBuy Now
QuidelOrtho
$36.3421.08%Jefferies
Tycho Peterson82%
 → $44UpgradeHold → BuyGet Alert
05/08/2025AWRBuy Now
American States Water
$80.244.69%Wells Fargo
Jonathan Reeder63%
$76 → $84UpgradeUnderweight → Equal-WeightGet Alert
05/08/2025IFFBuy Now
Intl Flavors & Fragrances
$73.9913.53%Barclays
Lauren Lieberman64%
$76 → $84UpgradeEqual-Weight → OverweightGet Alert
05/08/2025ROKBuy Now
Rockwell Automation
$296.93-8.73%JP Morgan
Stephen Tusa66%
$201 → $271UpgradeUnderweight → NeutralGet Alert

Recent Analyst Stock Rating Upgrade News

Former Employee Sues Musk's SpaceX, Claiming He Was Fired Over Bathroom Breaks
SpaceX faces a lawsuit from a former employee, who alleges discriminatory treatment and wrongful termination due to his chronic bowel disease.
Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $45
Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $54 to $45.
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $28 to $25.
UBS Maintains Buy on Cogent Comms Hldgs, Lowers Price Target to $75
UBS analyst Christopher Schoell maintains Cogent Comms Hldgs (NASDAQ:CCOI) with a Buy and lowers the price target from $102 to $75.
UBS Maintains Buy on Coterra Energy, Lowers Price Target to $30
UBS analyst Josh Silverstein maintains Coterra Energy (NYSE:CTRA) with a Buy and lowers the price target from $32 to $30.
UBS Maintains Buy on Jacobs Solutions, Lowers Price Target to $152
UBS analyst Steven Fisher maintains Jacobs Solutions (NYSE:J) with a Buy and lowers the price target from $154 to $152.
UBS Maintains Neutral on Molson Coors Beverage, Lowers Price Target to $59
UBS analyst Peter Grom maintains Molson Coors Beverage (NYSE:TAP) with a Neutral and lowers the price target from $63 to $59.
UBS Maintains Buy on Bio-Techne, Lowers Price Target to $70
UBS analyst Dan Leonard maintains Bio-Techne (NASDAQ:TECH) with a Buy and lowers the price target from $95 to $70.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved